Trials
Phase 3 study to assess the effect of AZD0780 on LDL-C in patients with HeFH (AZURE-HeFH) (NCT07000136)
Study title/design: A Phase 3 Study to assess the effect of AZD0780 on LDL-C in patients with HeFH (AZURE-HeFH) (NCT07000136) Trial NCT07000136. Not yet recruiting. Estimated primary and study completion 26 March 2027. Aim To evaluate the efficacy and safety of AZD0780 in adults with HeFH…
read more »
Phase 3 study of AZD0780 on major adverse CV events in patients with a history of ASCVD events or at high risk of a first event (AZURE-Outcomes) (NCT07000357)
Study title/design: Phase 3 study of AZD0780 on major adverse CV events in patients with a history of ASCVD events or at high risk of a first event (AZURE-Outcomes) (NCT07000357) Trial NCT07000357. Not yet recruiting. Estimated primary and study completion 26 October 2029. Aim To…
read more »
Phase 3 study to assess the effect of AZD0780 on LDL-C in patients with clinical ASCVD or at risk of a first ASCVD event (AZURE-LDL) (NCT07000123)
Study title/design: Phase 3 study to assess the effect of AZD0780 on LDL-C in patients with clinical ASCVD or at risk of a first ASCVD event (AZURE-LDL) (NCT07000123) Trial NCT07000123. Not yet recruiting. Estimated primary and study completion 26 March 2027. Aim To evaluate the…
read more »
A study to assess the efficacy, safety and tolerability of different doses of AZD0780 in patients with dyslipidaemia (NCT06173570) (PURSUIT)
Study title/design: A study to assess the efficacy, safety and tolerability of different doses of AZD0780 in patients with dyslipidaemia (NCT06173570) (PURSUIT) Trial NCT06173570 (Completed 30 September 2024). Aim To measure the effect of different daily doses of AZD0780 on LDL-C levels and other lipid…
read more »
Phase 1 randomised, single-blind, placebo-controlled study of AZD0780 (NCT05384262)
Study title/design: Phase 1 randomised, single-blind, placebo-controlled study of AZD0780 (NCT05384262) Trial First-in-human single ascending and multiple dose study of AZD0780 (NCT05384262) (Completed). Aim To assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of AZD0780 as monotherapy, and in addition to standard of care (rosuvastatin)…
read more »
CLEAR Outcomes: Bempedoic acid effects on major CV outcomes (NCT02993406)
Study title/design: CLEAR Outcomes: Bempedoic acid effects on major CV outcomes (NCT02993406) Trial NCT02993406 (Completed). Aim To determine if bempedoic acid decreases cardiovascular (CV) events in participants with or at high risk of CV disease who are statin intolerant. Study design Phase 3 randomised, double-blind,…
read more »
CLEAR Harmony Open Label Extension: Long term safety and tolerability of bempedoic acid (NCT03067441)
Study title/design: CLEAR Harmony Open Label Extension: Long term safety and tolerability of bempedoic acid (NCT03067441) Trial NCT03067441 (Completed) Aim To determine if bempedoic acid (ETC-1002) is safe and well tolerated in patients at high cardiovascular (CV) risk with elevated LDL-C not adequately controlled by…
read more »
CLEAR Harmony: Long term safety and tolerability of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02666664)
Study title/design: CLEAR Harmony: Long term safety and tolerability of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02666664) Trial NCT02666664 (Completed). Aim To determine if bempedoic acid (ETC-1002) is safe and well tolerated in patients at high cardiovascular (CV) risk with elevated…
read more »
CLEAR Wisdom: Long term efficacy of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02991118)
Study title/design: CLEAR Wisdom: Long term efficacy of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02991118) Trial NCT0299118 (Completed). Aim To determine if bempedoic acid (ETC-1002) is effective in patients at high cardiovascular (CV) risk with elevated LDL-C not adequately controlled by…
read more »
CLEAR Serenity: Bempedoic acid in patients with hyperlipidaemia and statin intolerance (NCT02988115)
Study title/design: CLEAR Serenity: Bempedoic acid in patients with hyperlipidaemia and statin intolerance (NCT02988115) Trial NCT02988115 (Completed). Aim To determine if bempedoic acid (ETC-1002) is effective and safe in patients with elevated LDL-C who are statin intolerant. Study design Phase 3 randomised, double-blind, placebo-controlled study…
read more »
CORALreef Outcomes: Enlicitide decanoate (MK-0616) in patients at high cardiovascular risk (NCT06008756)
Study title/design: CORALreef Outcomes: Enlicitide decanoate (MK-0616) in patients at high cardiovascular risk (NCT06008756) Trial NCT06008756/MK-0616-015 (Recruiting). Estimated primary completion: 29 November 2029. Estimated study completion: 29 November 2029. Aim To evaluate the efficacy of enlicitide decanoate (MK-0616) compared to placebo in increasing the time…
read more »
CORALreef HeFH: enlicitide decanoate (MK-0616) in adults with familial hypercholesterolaemia (CORALreef HeFH, NCT05952869)
Study title/design: CORALreef HeFH: enlicitide decanoate (MK-0616) in adults with familial hypercholesterolaemia (CORALreef HeFH, NCT05952869) Trial NCT05952869/MK-0616-017 (Active, not recruiting). Estimated primary completion: 28 April 2025. Estimated study completion: 28 April 2025. Aim To evaluate the efficacy, safety and tolerability of enlicitide decanoate (MK-0616) in…
read more »
CORALreef Lipids: Enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT059528456)
Study title/design: CORALreef Lipids: enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT059528456) Trial NCT059528456/MK-0616-013 (Active, not recruiting). Estimated primary completion: 15 August 2025. Estimated study completion: 15 August 2025. Aim To evaluate the efficacy, safety and tolerability of enlicitide decanoate (MK-0616) in lowering LDL-C in adults with…
read more »
Efficacy and safety of enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT05261126)
Study title/design: Efficacy and safety of enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT05261126) Trial NCT05261126/MK-0616-008 (Completed) Aim To assess the efficacy and safety of enlicitide decanoate (MK-0616) in lowering LDL-C in adults with hypercholesterolaemia Study design Phase 2b, randomised, double-blind, placebo-controlled study of oral MK-0616 6…
read more »
A study of VERVE-102 in patients with familial hypercholesterolaemia or premature coronary artery disease (NCT06164730)
Study title/design: A study of VERVE-102 in patients with familial hypercholesterolaemia or premature coronary artery disease (NCT06164730) Trial NCT06164730 (Recruiting) Estimated primary completion: August 2026 Estimated study completion: August 2026 Aim To evaluate the safety and pharmacodynamic profile of VERVE-102 in patients with familial hypercholesterolaemia…
read more »
Long term efficacy and safety of lerodalcibep (LIB003) in patients with HoFH, HeFH or high risk for CVD requiring further LDL-C reduction (LIBerate-OLE, NCT04798430)
Study title/design Long term efficacy and safety of lerodalcibep (LIB003) in patients with HoFH, HeFH or high risk for CVD requiring further LDL-C reduction (LIBerate-OLE, NCT04798430) Trial NCT04798430/LIB003-007 (Enrolling by invitation). Estimated primary completion: October 30 2024. Estimated study completion: December 31 2024. Aim To…
read more »
Trial to evaluate efficacy and safety of lerodalcibep (LIB003) and inclisiran in high risk CVD patients (LIBerate-VI) (NCT05004675)
Study title/design Trial to evaluate efficacy and safety of lerodalcibep (LIB003) and inclisiran in high risk CVD patients (LIBerate-VI) (NCT05004675) Trial NCT05004675/LIB003-012 (Active, not recruiting). Estimated primary completion: 30 May 2024. Estimated study completion: 30 July 2024. Aim To compare LDL-C reductions with lerodalcibep 300…
read more »
Study of efficacy and safety of lerodalcibep (LIB003) in patients with CVD on statins requiring additional LDL-C reduction (LIBerate-CVD) (NCT04797247)
Study title/design Study of efficacy and safety of lerodalcibep (LIB003) in patients with CVD on statins requiring additional LDL-C reduction (LIBerate-CVD) (NCT04797247) Trial NCT04797247/LIB003-005 (Completed) Aim To assess LDL-C reductions at week 52 with monthly (Q4W) dosing of lerodalcibep 300 mg s.c. compared to placebo…
read more »
Study to assess the efficacy and safety of lerodalcibep (LIB003) in patients with HeFH on oral lipid therapy needing further LDL-C reduction (LIBerate-FH) (NCT04797104)
Study title/design Study to assess the efficacy and safety of lerodalcibep (LIB003) in patients with HeFH on oral lipid therapy needing further LDL-C reduction (LIBerate-FH) (NCT04797104) Trial NCT04797104/LIB003-004 (Completed) Aim To assess LDL-C reductions at week 24 and the mean of weeks 22 and 24…
read more »
Study of long term efficacy and safety of lerodalcibep (LIB003) in patients with CVD or high risk for CVD needing further LDL-C Reduction (LIBerate-HR, NCT04806893)
Study title/design Study of long term efficacy and safety of lerodalcibep (LIB003) in patients with CVD or at high risk of CVD needing further LDL-C reduction (LIBerate-HR, NCT04806893) Trial NCT04806893/LIB003-006 (Completed) Aim To assess LDL-C reductions at week 52 with lerodalcibep 300 mg s.c. every…
read more »
